HAMILTON, N.J., July 19, 2018 /PRNewswire/ — Genesis Drug Discovery & Development (GD3) the contract research organization (CRO) of Genesis Biotechnology Group® (GBG), has announced the appointment of Olesia Buiakova, M.D., Ph.D., the Chief Scientific Officer of Invivotek as its new Chief Scientific Officer. In this capacity, as an expansion of Dr. Buiakova’s current role, she will be responsible for managing the entire integrated GD3 portfolio of drug discovery services from target validation and assay development to identification of clinical candidates. Dr. Buiakova will provide leadership, oversight and coordination for the development and management of new preclinical drug discovery platforms in oncology, immunology, metabolic and ocular diseases.
Dr. Buiakova began her career with GBG as the Vice President of Biology for Invivotek in 2013. Later that year, she transitioned into her current role as Chief Scientific Officer. As the Chief Scientific Officer of Invivotek she oversaw a multidisciplinary pre-clinical contract research team and was responsible for establishing and managing pre-clinical animal research programs for several big Pharma and biotech companies, including in vivo pharmacology programs for sister companies at GBG. Prior to joining GBG, Dr. Buiakova held multiple positions in the field of in vivo pharmacology including Director at Taconic CRO Division (formerly Xenogen Biosciences). She also was responsible for generating animal models of human diseases at Columbia Genome Center at Columbia University, New York, NY. Dr. Buiakova earned an MD in Medical Biochemistry at the Russian State Medical University in Moscow, Russia. She earned a Ph.D. in Molecular Biology at the Institute for Molecular Genetics of Russian Academy of Sciences in Moscow, Russia. Dr. Buiakova completed her post-doctoral fellowship in Molecular Neurobiology at Hoffmann-La Roche Institute for Molecular Biology in Nutley, NJ.
Dr. Buiakova has distinguished herself with over 20 years of experience in the pharmaceutical, biotechnology and CRO industries. “We are grateful to Olesia for her previous scientific leadership, and look forward to continuing to work closely with her in her newly expanded role as an advisor and collaborative partner to pharmaceutical, sponsor and academic organizations” said Dr. Eli Mordechai, CEO of Genesis Biotechnology Group.
GBG is a consortium of vertically integrated corporate research entities, which facilitates the overall market implementation and delivery of biomedical science products and services related to diagnostics and drug discovery. Through the consolidation of research activities, and the collaboration of diverse groups of scientists with expertise in molecular biology, genetics, high throughput screening (HTS), pharmacology, molecular modeling, and medicinal chemistry, GBG is well-positioned to create and sustain complex research platforms in drug discovery and the design of surrogate biomarkers for chronic diseases.
About Genesis Drug Discovery & Development
Genesis Drug Discovery & Development (GD3) offers a comprehensive portfolio of drug discovery services in multiple therapeutic areas. From point solutions to program management, our experts in preclinical drug discovery ensure the efficient development and coordination unique preclinical programs from discovery through candidate selection. By providing a single point-of-contact throughout the project lifetime, GD3 streamlines transitions between all phases of the discovery cycle to shorten timelines for faster project completion and potential market advantage. Our mission is to leverage decades of Pharma and CRO experience and expertise to advance OUR client’s mission of advancing therapies to patients and their physicians.
To find out more, please visit www.genesisbiotechgroup.com.
Contact: Prabal Banerjee, Ph.D., Business Development Executive
SOURCE Genesis Drug Discovery & Development